Sideris granted Novartis an exclusive option to acquire Sideris and its lead asset Sideris' SP-420 in a deal that would value the company at up to $300 million

Sideris Pharmaceuticals Inc.

U.S. / Private Biopharma

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Novartis AG

Switzerland / Large-Cap Biopharma (>=$50 billion)

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Proposed

Sample

01/01/2009

announced